LOGIN
AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women
March 2018
AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Abaloparatide Reduced the Risk of Major Nonvertebral Fractures in Postmenopausal Women with Osteoporosis
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
1645 postmenopausal women with osteoporosis were randomized with daily subcutaneous injections or either abaloparatide 80ug or placebo for 18 months. Participants were followed up for the incidence of major non-vertebral fracture over 18 months of treatment. Results demonstrated a significantly lower incidence of major non-vertebral fracture among participants who received abaloparatide compared t...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.